Cynata Therapeutics Limited (ASX:CYP)

Market Cap	33.89M
Revenue (ttm)	1.74M
Net Income (ttm)	-8.85M
Shares Out	225.95M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,044
Average Volume	209,121
Open	0.1600
Previous Close	0.1650
Day's Range	0.1500 - 0.1600
52-Week Range	0.1400 - 0.2850
Beta	0.79
RSI	42.75
Earnings Date	Aug 27, 2025

About Cynata Therapeutics

Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company’s lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease. It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; and CYP-006TK,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 2
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CYP

Financial Performance

In 2024, Cynata Therapeutics's revenue was 2.32 million, an increase of 39.98% compared to the previous year's 1.65 million. Losses were -9.74 million, -31.75% less than in 2023.